180 related articles for article (PubMed ID: 18240099)
1. Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans.
Woelkart K; Dittrich P; Beubler E; Pinl F; Schoop R; Suter A; Bauer R
Planta Med; 2008 May; 74(6):651-6. PubMed ID: 18240099
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and immunomodulatory effects of phytotherapeutic lozenges (bonbons) with Echinacea purpurea extract.
Guiotto P; Woelkart K; Grabnar I; Voinovich D; Perissutti B; Invernizzi S; Granzotto M; Bauer R
Phytomedicine; 2008 Aug; 15(8):547-54. PubMed ID: 18583121
[TBL] [Abstract][Full Text] [Related]
3. Absolute/relative bioavailability and metabolism of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes) after intravenous and oral single doses to rats.
Ardjomand-Woelkart K; Kollroser M; Magnes C; Sinner F; Frye RF; Derendorf H; Bauer R; Butterweck V
Planta Med; 2011 Nov; 77(16):1794-9. PubMed ID: 21604240
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue distribution of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides after oral administration in rats.
Woelkart K; Frye RF; Derendorf H; Bauer R; Butterweck V
Planta Med; 2009 Oct; 75(12):1306-13. PubMed ID: 19399718
[TBL] [Abstract][Full Text] [Related]
5. Absorption of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral application of Echinacea purpurea tincture.
Dietz B; Heilmann J; Bauer R
Planta Med; 2001 Dec; 67(9):863-4. PubMed ID: 11745026
[TBL] [Abstract][Full Text] [Related]
6. The role of alkamides as an active principle of echinacea.
Woelkart K; Bauer R
Planta Med; 2007 Jun; 73(7):615-23. PubMed ID: 17538868
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans.
Woelkart K; Koidl C; Grisold A; Gangemi JD; Turner RB; Marth E; Bauer R
J Clin Pharmacol; 2005 Jun; 45(6):683-9. PubMed ID: 15901750
[TBL] [Abstract][Full Text] [Related]
8. The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS.
Goey AK; Rosing H; Meijerman I; Sparidans RW; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 902():151-6. PubMed ID: 22770780
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system.
Woelkart K; Marth E; Suter A; Schoop R; Raggam RB; Koidl C; Kleinhappl B; Bauer R
Int J Clin Pharmacol Ther; 2006 Sep; 44(9):401-8. PubMed ID: 16995328
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Echinacea alkylamide pharmacokinetics between liquid and tablet preparations.
Matthias A; Addison RS; Agnew LL; Bone KM; Watson K; Lehmann RP
Phytomedicine; 2007 Sep; 14(9):587-90. PubMed ID: 17289362
[TBL] [Abstract][Full Text] [Related]
11. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion.
Matthias A; Addison RS; Penman KG; Dickinson RG; Bone KM; Lehmann RP
Life Sci; 2005 Sep; 77(16):2018-29. PubMed ID: 15919096
[TBL] [Abstract][Full Text] [Related]
12. Possible role of fat tissue in the pharmacokinetics of Dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral administration of Echinacea angustifolia extract in rats.
Jedlinszki N; Rédei D; Haller J; Freund TF; Hohmann J; Zupkó I
Nat Prod Commun; 2014 Jun; 9(6):843-5. PubMed ID: 25115096
[TBL] [Abstract][Full Text] [Related]
13. Comparative metabolomics approach coupled with cell- and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants.
Hou CC; Chen CH; Yang NS; Chen YP; Lo CP; Wang SY; Tien YJ; Tsai PW; Shyur LF
J Nutr Biochem; 2010 Nov; 21(11):1045-59. PubMed ID: 20005088
[TBL] [Abstract][Full Text] [Related]
14. Alkamides from Echinacea inhibit cyclooxygenase-2 activity in human neuroglioma cells.
Hinz B; Woelkart K; Bauer R
Biochem Biophys Res Commun; 2007 Aug; 360(2):441-6. PubMed ID: 17599805
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content.
Modarai M; Gertsch J; Suter A; Heinrich M; Kortenkamp A
J Pharm Pharmacol; 2007 Apr; 59(4):567-73. PubMed ID: 17430641
[TBL] [Abstract][Full Text] [Related]
16. Transport of alkamides from Echinacea species through Caco-2 monolayers.
Jager H; Meinel L; Dietz B; Lapke C; Bauer R; Merkle HP; Heilmann J
Planta Med; 2002 May; 68(5):469-71. PubMed ID: 12058332
[TBL] [Abstract][Full Text] [Related]
17. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties.
Barnes J; Anderson LA; Gibbons S; Phillipson JD
J Pharm Pharmacol; 2005 Aug; 57(8):929-54. PubMed ID: 16102249
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans.
Wittemer SM; Ploch M; Windeck T; Müller SC; Drewelow B; Derendorf H; Veit M
Phytomedicine; 2005 Jan; 12(1-2):28-38. PubMed ID: 15693705
[TBL] [Abstract][Full Text] [Related]
19. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts.
Chicca A; Raduner S; Pellati F; Strompen T; Altmann KH; Schoop R; Gertsch J
Int Immunopharmacol; 2009 Jul; 9(7-8):850-8. PubMed ID: 19303464
[TBL] [Abstract][Full Text] [Related]
20. Chromatographic methods for metabolite profiling of virus- and phytoplasma-infected plants of Echinacea purpurea.
Pellati F; Epifano F; Contaldo N; Orlandini G; Cavicchi L; Genovese S; Bertelli D; Benvenuti S; Curini M; Bertaccini A; Bellardi MG
J Agric Food Chem; 2011 Oct; 59(19):10425-34. PubMed ID: 21830789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
